Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children

June 22, 2022

From Merck & Co., Inc.

Via Business Wire

Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence

June 21, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health

June 21, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults

June 21, 2022

From Merck & Co., Inc.

Via Business Wire

FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection

June 13, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference

June 08, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study

June 07, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline

June 07, 2022

From Merck & Co., Inc.

Via Business Wire

Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial

June 05, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Third-Quarter 2022 Dividend

May 24, 2022

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence

May 24, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection

May 20, 2022

From Merck & Co., Inc.

Via Business Wire

Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)

May 10, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in Bank of America Securities 2022 Healthcare Conference

May 04, 2022

From Merck & Co., Inc.

Via Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

April 29, 2022

From Merck & Co., Inc.

Via Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

April 29, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces First-Quarter 2022 Financial Results

April 28, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

April 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022

April 20, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

April 14, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28

April 08, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need

April 05, 2022

From Merck & Co., Inc.

Via Business Wire

Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access

April 04, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children

April 01, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo

April 01, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer

March 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

March 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer

March 23, 2022

From Merck & Co., Inc.

Via Business Wire

Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT

March 22, 2022

From Merck & Co., Inc.

Via Business Wire

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation

March 21, 2022

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Merck & Co., Inc.

Starting at /week.